The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19.

ABSTRACT: The severity of COVID 19 symptoms has a direct correlation with lymphopenia, affecting natural killer (NK) cells. SARS-CoV-2 specific "memory" NK cells obtained from convalescent donors can be used as cell immunotherapy. In 2022 a phase I, dose-escalation, single center clinical trial was conducted to evaluate the safety and feasibility of the infusion of CD3^-/CD56⁺ NK cells against moderate/severe cases of COVID-19 (NCT04578210). Six participants with pneumonia and/or lymphopenia were infused. Four patients received a single-dose infusion of NK cells of 1×10⁶/kg, and the following two patients a dose of 2×10⁶/kg of NK cells. All participants' clinical status and inflammation markers were monitored. No serious adverse events were reported after i

SUBMITTER: Hernandez-Blanco C 

PROVIDER: S-EPMC11772958 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature